Pancreatic Cancer Incidence and Fatalities Rise in Australia, Prompting Calls for Increased Awareness and Research

Pancreatic cancer is projected to become Australia's second most lethal cancer by 2030, presenting a significant health challenge due to late detection, vague symptoms, and a low five-year survival rate of just 13-14%. Amidst rising mortality and diagnoses, particularly among younger populations, Australia is promoting new clinical guidelines for general practitioners and launching pilot studies to improve early diagnosis and patient outcomes.

The Growing Threat of Pancreatic Cancer

Pancreatic cancer cases and deaths are on a substantial rise in Australia. Research from Flinders University in 2024 reveals a 200 percent rise in cases among Australians aged 15-49 over the past 24 years, mirroring a global trend in affluent nations. Overall, diagnoses are estimated to have tripled over the last four decades, from approximately 1,200 to 4,000 new cases annually.

The disease's lethality is escalating rapidly. Data from the Australian Bureau of Statistics shows that pancreatic cancer deaths have nearly doubled in the past two decades, growing at 2.6 times the rate of all cancer-related deaths. In 2024, it surpassed prostate cancer in fatalities, with only lung cancer causing more deaths. The increase in deaths accelerated by 40% between 2015 and 2024, compared to a 27% rise in the preceding decade. Consequently, pancreatic cancer now accounts for approximately 1 in 14 cancer deaths in 2024, up from 1 in 20 in 2005. It is currently Australia's third-leading cause of cancer-related deaths, responsible for over 4,000 deaths last year. The average age of diagnosis is 72.

Challenges in Detection and Survival

Early detection of pancreatic cancer remains profoundly difficult. The pancreas is situated deep within the body, making it impossible to feel externally. Symptoms are often non-specific and easily mistaken for minor ailments, leading to late diagnoses. Definitive diagnosis typically requires invasive procedures like scans or biopsies.

The average five-year survival rate for pancreatic cancer is strikingly low, at approximately 13-14%. This is largely attributed to the advanced stage—often stage three or four—at which the cancer is typically detected.

At these advanced stages, surgical removal of the primary tumor is frequently unfeasible, and treatment often becomes palliative, focusing on controlling the disease and alleviating pain. Australia currently lacks a national screening program for pancreatic cancer, and patients often endure a significantly poorer quality of life due to arduous treatments and high morbidity.

Understanding Risk Factors and Associated Conditions

Several factors contribute to the risk of developing pancreatic cancer:

• Lifestyle Factors: Smoking is a major global risk factor. Heavy alcohol consumption and obesity also increase risk. Raised blood glucose is a significant contributor, especially for early-onset pancreatic cancer in Australia and Oceania.
• Medical Conditions: Long-term type 2 diabetes and chronic pancreatitis are notable risks. While elevated blood sugar alone may not directly increase risk, insulin resistance, poorly controlled blood sugar, and pancreatic inflammation linked to long-standing diabetes are implicated. UK research suggests diabetes can nearly double the risk. The Australian Institute of Health and Welfare reports type 2 diabetes as Australia's fastest-growing chronic condition, with diagnoses among 21-39 year olds rising by 44 percent in the last decade, and by 17 percent for those under 20. Approximately 1 in 175 adults over 50 with diabetes may develop pancreatic cancer due to a tumor.
• Genetic and Hereditary Factors: A family history of pancreatic cancer, including mutations in BRCA1 and BRCA2 genes.
• Age: Most cases occur after the age of 60.
• Environmental Factors: Long-term exposure to certain workplace chemicals.

Symptoms to Watch For

Pancreatic cancer symptoms often manifest only after the cancer has grown large enough to impact other organs or has spread. Key indicators include:

• Persistent upper abdominal pain (below ribs or breastbone), which may also extend as severe back pain.
• Unexplained weight loss and loss of appetite.
• Nausea and vomiting, persistent fatigue.
• Jaundice (yellowing of the skin or eyes) and itchy skin, often due to liver malfunction or bile duct obstruction.
• Dark urine.
• Changes in bowel movements: pale, loose, unusually foul-smelling stool that is difficult to flush, or changes such as diarrhea or constipation.
• The sudden onset of diabetes.

As the disease progresses, cachexia (cancer-induced wasting syndrome) can develop, leading to significant loss of body mass and muscle.

Current Initiatives and Research Efforts

Australia is responding to the challenges of pancreatic cancer with several key initiatives:

• GP Recommendations: New recommendations for general practitioners, developed by Australian clinicians and scientists, are being actively promoted. These guidelines aim to help doctors identify patients requiring further investigation for pancreatic cancer based on combinations of symptoms and risk factors, such as abdominal pain combined with smoking, heavy drinking, or obesity. The University of Queensland developed clinical guidance and educational tools for primary care practitioners to aid in symptom recognition, initial investigations, and timely specialist referrals, including monitoring guidance for high-risk individuals.
• Pilot Study for Early Detection: An Australia-wide pilot study, the Pancreatic Cancer New Onset Diabetes Study (PaCNOD), led by Professor Rachel Neale of Queensland's QIMR Berghofer, is exploring early diagnosis methods. The study is recruiting individuals over 55 recently diagnosed with Type 1 or Type 2 diabetes (without prior pancreatic cancer or pancreas removal). It seeks to determine if non-invasive CT scans could lead to earlier detection in high-risk populations.
• National Roadmap and Resources: Cancer Australia developed the National Pancreatic Cancer Roadmap, a comprehensive framework with 33 priority domains. To support this, Cancer Australia collaborated with universities and the Pancare Foundation to create evidence-based resources for health professionals and patients, addressing challenges in early detection, timely diagnosis, pain management, and the early integration of palliative care. The University of Melbourne, in partnership with HammondCare, the University of Queensland, and the University of Adelaide, specifically developed resources for pain management and palliative care, including standardized referral pathways, pain assessment tools, and culturally appropriate guidance for Aboriginal and Torres Strait Islander peoples.
• Advocacy and Awareness: Organizations like Pankind and the Pancare Foundation are vital in supporting patients, raising awareness, and fundraising. Patient advocates, such as Mona Thind (whose tumor was detected and removed early) and Carol Chevalier (whose tumor was incidentally discovered), share their stories to highlight the importance of early detection and foster support groups.

Federal Health Minister Mark Butler has highlighted government investments in cancer nurses and improved access to immunotherapy, noting that a review of Health Technology Assessment is underway to facilitate faster access to advanced medical treatments.

A Call for National Priority and Future Directions

There are growing calls for pancreatic cancer to be designated a national health priority in Australia, necessitating sustained, long-term investment across several crucial areas:

• Research: Critical investment is needed for:
  • Early detection technologies, including reliable biomarkers and advanced imaging.
  • Surveillance of high-risk populations.
  • Personalized treatment approaches through genomic profiling and precision medicine.
  • Professor Mehrdad Nikfarjam, a leading surgeon, advocates for increased investment in innovative research for upper GI cancers, noting that targeted therapies for other cancers may not be directly applicable.
• Clinical Innovation and Workforce Development: Enhanced support for clinical trials and specialized training for healthcare professionals.
• Equitable Access to Care: Ensuring all patients have access to diagnosis, treatment, and supportive services, including expanded access to integrated supportive and palliative care models.
• Public Awareness and Education: Improved public understanding of risk factors and symptoms is crucial for earlier presentation to medical professionals.

Recognizing pancreatic cancer as a national health priority and committing to these investments is considered essential to alter the trajectory of the disease and significantly improve outcomes for affected individuals and families in Australia.